What we learnt on Day 1 of Aids conference
Movie star Charlize Theron kicked off the opening of the International Aids Society conference in Amsterdam on Tuesday‚ speaking out against the stigmatisation of sex workers and drug users‚ who have much higher rates of HIV than other people.
Sir Elton John also spoke about the work his $10-million fund does to help gay men‚ lesbians and bisexual people with HIV prevention and treatment. By the way‚ he funds SA programmes for gay men‚ too.
Prince Harry joined him on stage – and after the celebs had done their bit‚ the world’s leading HIV scientists got down to releasing the latest research results.
South African scientist Professor Linda Gail Bekker of the University of Cape Town is the head of the conference‚ being attended by 15‚000 people.
Here is a summary from Day 1:
1. Have sex without a condom and stay safe
Scientists measured 75‚000 condomless sex acts between 972 gay couples where one man was HIV positive and the other negative. Not a single person contracted HIV from their partners. This is because the HIV positive men had undetectable viral loads‚ meaning they took their ARV treatment so well that the virus was not replicating in them.
This study is further evidence that an undetectable viral load – which can be easily measured – means a person cannot pass on HIV and thus can avoid using condoms. This result has been found many times‚ but only among large trials of straight couples.
Gay sex is biologically more risky‚ so this study confirms that people with an undetectable viral load won’t pass on the virus‚ no matter the type of sex they have.
This scientific fact is advertised with the slogan U=U: Undetectable means Untransmitable.
2. Two drugs keep HIV under control as well as three
It is the norm that all antiretroviral treatment requires three drugs to prevent the body becoming resistant to the drugs. Even the South African government-provided single pill a day consists of three different ARV medicines.
But a trial in Argentina and parts of Africa‚ Europe and Asia Pacific show a new medicine of two drugs‚ called Dolutegravir and Lamivudine‚ worked as well as a common ARV drug with three medicines.
In the study‚ 1‚400 HIV-positive adults were put on treatment for first time and half got the new treatment and the other half the three drugs. Their health was later compared.
Researchers said the two-in-one treatment could "be an opportunity to reduce treatment costs and reduce side effects".
3. More concern about birth defects in HIV wonder drug
Dolutegravir is a newish HIV drug expected to be used in South Africa next year‚ instead of a drug currently used now called Efavirenz. It has almost no side effects and people do not become resistant to it.
There is one recorded case of resistance of the 600‚000 people using it abroad in America and Europe‚ Wits Reproductive Health and HIV Institute Professor Francois Venter has previously told this publication.
The fact you can’t become resistant to Dolutegravir means the medicine won’t stop working and leave users to die from Aids.
But now Dolutegravir has been linked to birth defects of babies born to four women in Botswana using the drug. This is a very initial finding and may not be confirmed in a bigger trial‚ researchers have cautioned.
However‚ protesters‚ including South African women at conference‚ demanded to be offered the new drug as it has so few side effects and said not “every woman is a birth machine”.
In other words‚ they asked that it be offered to woman who are not planning to fall pregnant or are past child-bearing age.
4. Another trial for a cure fails
A new cure study titled RIVER – conducted by researchers from Imperial College London – showed strategies to kick out HIV hiding in cells called “reservoirs” and then kill the virus failed.
After using ARVs to stop the virus replicating‚ scientists have long struggled to track down the leftover HIV‚ which hides in the body and is invisible to the immune system.
Now using a lymphoma cancer drug they can kick it out of its hiding places for the immune system to see. This trial added a treatment vaccine to boost the immune system to help it kill the now visible HIV.
The trials are called “Kill and Kick” trials. This particular trial done on 60 people failed. Only the “kick” part worked.
Scientists‚ led by Sarah Fidler of Imperial College‚ said they were now analysing results to try and understand why they could not kill the virus.
5. Feminising hormones for transgender women confuse HIV prevention drug
If you are a transgender woman‚ you may want to know that studies found when Thai transgender woman took hormonal treatment to transition from being born male to female‚ the hormone interfered with ARV prevention drug: tenofovir.
A press release explained that the “feminising hormone” can affect the prevention of HIV as it interferes with the action of the prevention drug taken daily.
But study researcher Akarin Hiransuthikul of the Thai Red Cross Aids Research Centre said the preliminary study did not prove this effect and called for more studies to see if this was definitely true.
Would you like to comment on this article or view other readers' comments? Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.